GLP-1 medications are gamechangers for weight loss and metabolic care. Investor opportunities are surging as patient demand, provider adoption, drug development, and positive health outcomes soar.

But as adoption accelerates, so do the legal, regulatory, and investment risks. This webinar will provide a focused briefing on the most pressing issues facing healthcare providers, drug companies, and investors amid the GLP-1 boom, including:

• History of GLP-1s and drug shortage lists
• Current FDA policies and guidance, including best practices when considering advertising and marketing practices, a primer on 503A vs. 503B pharmacy implications, and sourcing implications
• State law variability and considerations, including remote prescribing practices and considerations for innovative and multi-state practice models
• Compliance best practices
• Enforcement and litigation outlook